Magnesium and magnesium alloys have the potential to become a revolutionary material for a variety of industries because of their lightweight structure and ability to quickly biodegrade in water or inside the human body. Researchers, however, are still struggling to process this very reactive metal to eliminate defects that accelerate corrosion.
McGowan Institute for Regenerative Medicine affiliated faculty member Richard Debski, PhD, professor of bioengineering at the University of Pittsburgh and the co-director of the Orthopedic Robotics Laboratory, is a member of a team of researchers on a project which received $400K from the NIH to design and test a miniature, implantable, and battery-free sensor to monitor spinal fusion progress after surgery.
The recent Pittsburgh Post-Gazette newspaper article by Jill Daly highlights the significant challenges infants and children face if they require a heart transplant.
Renerva, LLC, a medical device company developing innovative technologies for peripheral nerve repair, announced recently that it has received two additional grants totaling $500,000 from the National Science Foundation (NSF) and the National Institutes of Health (NIH), rapidly accelerating development of their medical device products.
While 3D printing soft materials, such as silicone or proteins, offers many advantages, it also introduces many new and complicated variables to consider when creating a new part, per Vanesa Listek for 3D Print in her report featuring the work of McGowan Institute for Regenerative Medicine affiliated faculty member Newell Washburn, PhD, professor of biomedical engineering and chemistry at Carnegie Mellon University (CMU). The existing soft materials that can be 3D printed commercially are somewhat limited since they don’t have all the properties that researchers need to fully advance their developments and they end up working within the constraints of the current technology.
McGowan Institute for Regenerative Medicine affiliated faculty member Keith Cook, PhD, a professor of biomedical engineering at Carnegie Mellon University (CMU), is working to give new hope to patients with chronic lung disease.
The Disabled Veterans National Foundation (DVNF), a nonprofit veterans service organization that provides critically needed support to disabled and at-risk veterans who leave the military wounded—physically or psychologically—after defending our safety and our freedom, presented a grant of $50,000 to the Human Engineering Research Laboratories (HERL).
Technology developed in the McGowan Institute Medical Devices Lab under the leadership of William Federspiel, PhD, William Kepler Whiteford Professor of Bioengineering, Chemical Engineering, and Critical Care Medicine, has been incorporated into products for clinical use by ALung, a University of Pittsburgh spinout company. Dr. Federspiel is the Head of the Scientific Advisory Board and co-founder of ALung Technologies, Inc. The ALung devices are now being evaluated in several clinical trials. ALung is the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure.
Krzysztof Matyjaszewski, PhD, the J.C. Warner University Professor of Natural Sciences in the Department of Chemistry at Carnegie Mellon University (CMU) and a McGowan Institute for Regenerative Medicine affiliated faculty member, along with researchers from CMU’s Mellon College of Science and College of Engineering have developed a semiliquid lithium metal-based anode that represents a new paradigm in battery design. Lithium batteries made using this new electrode type could have a higher capacity and be much safer than typical lithium metal-based batteries that use lithium foil as anode. The semiliquid metal anode could be used to create high capacity batteries for electric vehicles and specialized batteries for use in wearable devices that require flexible batteries, examples of far-reaching impact.
Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre-treated with off-label selective vasodilator drugs, according to new research published in Circulation: Heart Failure, an American Heart Association journal. McGowan Institute for Regenerative Medicine Deputy Director Robert Kormos, MD, FAHA, Professor of Cardiothoracic Surgery and Bioengineering at the University of Pittsburgh, past director of UPMC’s Artificial Heart Program, and the Brack G. Hattler Chair of Cardiothoracic Transplantation, is a co-author on this study.
A team of polymer chemists and engineers from Carnegie Mellon University (CMU) including McGowan Institute for Regenerative Medicine affiliated faculty member Krzysztof Matyjaszewski, PhD, the J.C. Warner Professor of Natural Sciences at CMU, has developed a new methodology that can be used to create a class of stretchable polymer composites with enhanced electrical and thermal properties. These materials are promising candidates for use in soft robotics, self-healing electronics and medical devices. The results are published in Nature Nanotechnology.
Pelvic organ prolapse (POP) is a condition where the organs in the pelvis push against the vagina, creating a “bulge” that can extend outside of the body. It results from a weakening of the muscles and tissues that help support the pelvic organs. This disorder affects many women, but surgical treatments with polypropylene mesh – devices initially designed for hernia repairs, not vaginal use – often result in complications.
Inari Medical, Inc. announced the publication of its 106-patient prospective multicenter FlowTriever Mechanical Pulmonary Embolectomy (FLARE) study for the treatment of intermediate-risk pulmonary embolism (PE). The study was published in JACC: Cardiovascular Interventions. FLARE was conducted under the direction of co-principal investigators, Kenneth Rosenfield, MD, Section Head for Vascular Medicine and Intervention at Massachusetts General Hospital, Boston, and Victor Tapson, MD, Associate Director, Pulmonary and Critical Care Division at Cedars-Sinai Medical Center, Los Angeles.
Starfish can repair injured arms and reptiles can regrow severed tails; from bacteria to humans, every species is capable of regeneration, albeit to variable extents. These functions help make species more resilient, but how can we apply the knowledge of these regenerative mechanisms to improve human health? The University of Pittsburgh Department of Bioengineering has been collaboratively working to address this question through research efforts in tissue engineering and regenerative medicine.
Technology developed in the McGowan Institute Medical Devices Lab under the leadership of William Federspiel, PhD, William Kepler Whiteford Professor of Bioengineering, Chemical Engineering, and Critical Care Medicine has been incorporated into products for clinical use by ALung, a University of Pittsburgh spinout company. Dr. Federspiel is the Head of the Scientific Advisory Board and co-founder of ALung Technologies, Inc. The ALung devices are now being evaluated in several clinical trials. ALung is the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure.
McGowan Institute for Regenerative Medicine affiliated faculty member John Kellum, MD—Professor in the Departments of Critical Care Medicine, Medicine, Bioengineering, and Clinical and Translational Science at the University of Pittsburgh and the Director of the Center for Critical Care Nephrology and the Vice-Chair for Research, both appointments in the Department of Critical Care Medicine—is the lead investigator on a pilot study for the RenalSense® Clarity RMS® critical care monitoring system being conducted at the University of Pittsburgh Medical Center (UPMC).
The Pennsylvania Pediatric Medical Device Consortium (PPDC) has announced a partnership with two programs at the University of Pittsburgh. Formerly the Philadelphia Pediatric Medical Device Consortium, the PPDC’s new name reflects its statewide reach. This expansion comes on the heels of a five-year, $6 million grant renewal from the Consortium’s sponsor, the U.S. Food and Drug Administration.
Inari Medical, Inc. announced the enrollment of the first patient in the FlowTriever All-Comer Registry for Patient Safety and Hemodynamics (“FLASH”) using the FlowTriever® System for the treatment of pulmonary embolism (PE). McGowan Institute for Regenerative Medicine affiliated faculty member Catalin Toma, MD, Interventional Cardiologist, UPMC Presbyterian, is the Principal Investigator for FLASH.
The U.S. Food and Drug Administration announced that it has awarded five grants totaling up to $6 million per year over the next five years to Pediatric Device Consortia (PDC) across the country that will provide advice and support services to innovators of children’s medical devices.
McGowan Institute for Regenerative Medicine affiliated faculty member Rory Cooper, PhD, FISA & Paralyzed Veterans of America Professor and Distinguished Professor of the Department of Rehabilitation Science & Technology, professor of Bioengineering, Physical Medicine & Rehabilitation, and Orthopedic Surgery at the University of Pittsburgh, and Founding Director and VA Senior Research Career Scientist of the Human Engineering Research Laboratories—a VA Rehabilitation R&D Center of Excellence in partnership with Pitt—participated in the recent VA Research Fair in Washington, DC. He demonstrated MEBot, a wheelchair which can climb stairs.
It seems like something straight out of a science fiction movie: humans wearing bionic technology to move more easily.
Chronic brain implants are long-term devices used to record brain activity or stimulate neurons with electrical pulses and are a crucial component of neuroprosthetics. The performance of these devices depends on the host tissue response, which is often inflammatory and results in device performance degradation. McGowan Institute for Regenerative Medicine affiliated faculty member Takashi Kozai, PhD, assistant professor of bioengineering at the University of Pittsburgh Swanson School of Engineering, was awarded an NIH R21 grant to improve device design by investigating the role of oligodendrocytes and oligodendrocyte progenitor cells in this process.
Researchers at Carnegie Mellon University have developed a low-cost 3-D bioprinter by modifying a standard desktop 3-D printer, and they have released the breakthrough designs as open source so that anyone can build their own system. The researchers—Carnegie Mellon University (CMU) Materials Science and Engineering (MSE) and Biomedical Engineering (BME) Associate Professor Adam Feinberg, PhD, BME postdoctoral fellow TJ Hinton, PhD, and Kira Pusch, a recent graduate of the MSE undergraduate program—recently published a paper in the journal HardwareX that contains complete instructions for printing and installing the syringe-based, large volume extruder (LVE) to modify any typical, commercial plastic printer.
Implanted devices send targeted electrical stimulation to the nervous system to interfere with abnormal brain activity, and it is commonly assumed that neurons are the only important brain cells that need to be stimulated by these devices. However, research published in Nature Biomedical Engineering reveals that it may also be important to target the supportive glial cells surrounding the neurons.
Artificial lungs have long been used to help sick children until a lung transplant is available.
While these devices are helpful in supplying oxygen to children suffering from cystic fibrosis, pulmonary hypertension, and pulmonary fibrosis, among other diseases, during the wait for lung transplants, they restrict mobility.
As reported by Liz Beaulieu for HME News, McGowan Institute for Regenerative Medicine affiliated faculty member David Brienza, PhD, professor in the Department of Rehabilitation Science and Technology and associate dean for research in the School of Health and Rehabilitation Sciences (SHRS), and researchers at the University of Pittsburgh have secured a nearly $5 million grant to continue their work developing standards to improve product quality and safety for wheelchairs.
Virginia Tech and the Smithsonian’s National Museum of American History presented the first annual ACCelerate: ACC Smithsonian Creativity and Innovation Festival on October 13-15, 2017. The festival, programmed by Virginia Tech’s Institute for Creativity, Arts, and Technology and the Museum’s Lemelson Center for the Study of Invention and Innovation, was a 3-day celebration of creative exploration and research at the nexus of science, engineering, arts, and design (SEAD). Visitors to the festival interacted with innovators and experienced new interdisciplinary technologies developed to address global challenges. The event was free and open to the public.
ALung Technologies, Inc., was founded in 1997 by McGowan Institute for Regenerative Medicine faculty members William Federspiel, PhD, Professor of Bioengineering at the University of Pittsburgh, and the late Brack Hattler, MD, a renowned cardiothoracic surgeon. Drs. Federspiel and Hattler and the team from the McGowan Institute Medical Devices Laboratory developed the original Hemolung technology which was subsequently licensed by ALung for commercial development. The Hemolung Respiratory Assist System (RAS) has been approved outside of the United States since 2013 and is commercially available in major European markets.
Controlling fluid flow at the micro- and nano-level can enable the development of self-operating microfluidic devices and even small-scale factories that perform chemical synthesis and biomedical assays, as well as drive robotic systems operating in harsh environments. The stumbling block, however, is devising effective ways to regulate the movement of the fluids at such small, confined levels.
McGowan Institute for Regenerative Medicine faculty member Bryan Brown, PhD, is an Assistant Professor in the Department of Bioengineering with a secondary appointment in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of Pittsburgh. Recently, he discussed with Liz Reid of National Public Radio’s WESA his current research with different bioactive coatings to modulate the immune response to implanted devices.
The McGowan Institute for Regenerative Medicine congratulates McGowan Institute for Regenerative Medicine affiliated faculty members …
The University of Pittsburgh’s Center for Medical Innovation (CMI) awarded grants totaling $65,000 to three proposals through its 2017 Round-1 Pilot Funding Program for Early Stage Medical Technology Research and Development. Two of the three projects funded include McGowan Institute for Regenerative Medicine affiliated faculty members as part of their leadership teams. Award details include:
McGowan Institute for Regenerative Medicine faculty member William Federspiel, PhD, William Kepler Whiteford Professor in the Department of Bioengineering, Chemical Engineering, and Critical Care Medicine and the Director of the Medical Devices Laboratory at the McGowan Institute, recently spoke to Pittsburgh’s NPR News Station WESA about current research and pre-clinical trial efforts towards the development of a wearable artificial lung for patients suffering from lung failure. The new device promises to deliver greater mobility and increased odds for survival following severe lung damage.
As a rule, implants and the immune system don’t get along. The human body recognizes these materials as foreign substances and tries to fight them like a virus or bacteria. Although this response can cause trouble for doctors and patients, new research at the University of Pittsburgh suggests the immune system can actually assist the body in accepting implanted biomaterials.
From core technology developed at the McGowan Institute for Regenerative Medicine by William Federspiel, PhD, William Kepler Whiteford Professor in the Department of Bioengineering, Chemical Engineering, and Critical Care Medicine, and the late Brack Hattler, MD, ALung Technologies, Inc., has designed and developed a medical device that removes carbon dioxide and delivers oxygen to the bloodstream, replacing intubation where oxygen is delivered to the patient through a tube that is placed into the entrance to the lungs. ALung announced recently the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking approval to conduct a pivotal clinical study of the Hemolung Respiratory Assist System for the treatment of adults with severe acute exacerbations of chronic obstructive pulmonary disease (COPD).
Based on core technology developed by McGowan Institute of Regenerative Medicine faculty members William Federspiel, PhD, W.K. Whiteford professor of bioengineering, chemical engineering, and critical care medicine, and the late Brack Hattler, MD, ALung Technologies, Inc., is today a leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure. The company announced recently the closing of a $36 million Series C financing, including existing convertible notes. The round was led by Philips and UPMC, through its innovation and commercialization arm UPMC Enterprises, with other new and existing investors participating. The funding will support a planned US-based pivotal trial for FDA approval of the company’s Hemolung Respiratory Assist System (RAS), a minimally invasive artificial lung device which removes carbon dioxide independently of the lungs through a process called Respiratory Dialysis®.
A new waterproof motorized wheelchair that runs entirely on compressed air was unveiled recently at Morgan’s Wonderland, a 25-acre theme park in San Antonio, Texas. The park was built specifically for individuals with disabilities, and 10 of these chairs will be available to patrons at the venue’s new splash park, Morgan’s Inspiration Island, when it opens later this spring.
UPMC/University of Pittsburgh researchers’ latest work toward developing a prosthetic arm with a brain-computer interface was voted as the #1 most innovative idea in 2016 by the readers of STAT, a national publication focused on finding and telling compelling stories about health, medicine, and scientific discovery. There were 32 total pioneering discoveries considered in the voting.
University of Pittsburgh researchers have developed and tested a wearable artificial lung (pictured) that eventually could be used by patients with advanced lung disease. The new device, which showed positive results in pre-clinical tests, promises to deliver greater mobility and increased odds for survival following severe lung damage.
As reported by Casey Adams for Inside UPMC, 20 students from North Carolina Agricultural & Technical State University (NC A&T) who are enrolled in University of Pittsburgh’s distance learning class, “Artificial Organs,” recently made a 7-hour trek from their university to visit the Procirca Perfusion Simulation and Education Center at UPMC Shadyside. The course is conducted by McGowan Institute for Regenerative Medicine faculty member Harvey Borovetz, PhD, Distinguished Professor and former Chair (2002-2013) in the Department of Bioengineering, Swanson School of Engineering at the University of Pittsburgh, the Robert L. Hardesty Professor in the Department of Surgery, University of Pittsburgh School of Medicine, a Professor of Chemical and Petroleum Engineering, a Professor – Clinical and Translational Science Institute, a University Honors College Faculty Fellow, and within the McGowan Institute, the Deputy Director of Artificial Organs and Medical Devices.
